EUVIMEDEUVIMED entdecken
Crossref

Defining Favorable Prognosis in Bone Metastatic Hormone‐Sensitive Prostate Cancer Treated With Androgen Receptor Signaling Inhibitors

Dai Koguchi iD, Hideyasu Tsumura iD, Ken-Ichi Tabata iD, Takefumi Satoh iD, Kohei Mori iD, Shuhei Hirano iD, Masaomi Ikeda iD, Shinji Kurosaka, Junichiro Ishii, Daisuke Ishii iD, Kazumasa Matsumoto iD

The Prostate · 2026

DOI: 10.1002/pros.70152 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Prostate, 2026. Verfasst von Dai Koguchi und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Kitasato University School of Medicine, Sagamihara, Kanagawa, Japan. Hauptthemen laut MEDLINE: Bone Neoplasms, Prostatic Neoplasms, Androgen Receptor Antagonists. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 43 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

This study aimed to identify patients who would benefit from androgen receptor signaling inhibitor (ARSI) therapy in metastatic hormone‐sensitive prostate cancer (mHSPC) with bone metastasis (BM). Therefore, we developed a risk stratification model based on the prognostic impact of BM number.

Methods

We retrospectively analyzed 244 patients with mHSPC and BM treated with ARSI plus androgen deprivation therapy between March 2018 and November 2024. Prognostic thresholds for BM number were assessed using four cutoffs (≥ 4, ≥ 6, ≥ 11, and ≥ 21). The cutoff with the highest hazard ratio (HR) for castration resistance‐free survival (CRFS) was incorporated into a multivariable Cox model along with other clinical variables. Independent prognostic factors were used to construct a risk stratification model, and CRFS and overall survival (OS) were compared with the CHAARTED criteria.

Results

At a median follow‐up of 31.3 months, ≥ 11 BM showed the strongest prognostic effect for CRFS (HR: 2.62) and OS (HR: 3.01). Multivariable analysis identified ≥ 11 BM (HR: 2.47, 95% CI: 1.45–4.21, p = 0.001), ≥ Gleason score (GS) 9 (HR: 2.07, 95% CI: 1.12–3.45, p = 0.005), and ≥ cT3b (HR: 2.16, 95% CI: 1.14–4.07, p = 0.018) as independent adverse factors. Patients were classified into favorable‐risk (no risk factors), intermediate‐risk (one risk factor), and poor‐risk (two risk factors) groups, which demonstrated significantly different CRFS and OS outcomes (both p < 0.001). Compared with the low‐volume disease, as defined by the CHAARTED criteria, the favorable‐risk group represented a significantly larger proportion of patients (39.3% vs. 26.6%, p < 0.001) with comparable CRFS (HR: 0.66, p = 0.33) and OS (HR: 0.51, p = 0.18).

Conclusions

This risk model suggests that patients without ≥ 11 BM, ≥ GS9, and ≥ cT3b may benefit from ARSI plus androgen deprivation therapy for mHSPC. Moreover, it identifies a significantly larger favorable‐risk subgroup than the CHAARTED criteria, potentially enhancing clinical precision in treatment selection.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Bone NeoplasmsProstatic NeoplasmsAndrogen Receptor AntagonistsHumansMalePrognosisRetrospective StudiesAgedReceptors, AndrogenMiddle AgedSignal TransductionAged, 80 and over

Stichwörter der Autor:innen

bone metastasisprostate cancerrisk stratification modeltreatment

Substanzen

Androgen Receptor AntagonistsReceptors, Androgen

Autor:innen und Institutionen

  • Department of Urology, Kitasato University School of Medicine, Sagamihara, Kanagawa, Japan.
  • Department of Urology, Kitasato Institute Hospital, MInato, Tokyo, Japan.
  • Department of Urology, Sagmihara Kyodo Hospital, Sagamihara, Kanagawa, Japan.
  • Department of Urology, International University of Health and Welfare Atami Hospital, Atami, Shizuoka, Japan.

ORCID-Profile: Dai Koguchi, Hideyasu Tsumura, Ken-Ichi Tabata, Takefumi Satoh, Kohei Mori, Shuhei Hirano, Masaomi Ikeda, Daisuke Ishii, Kazumasa Matsumoto

Zitieren

APA

Koguchi, D., Tsumura, H., Tabata, K. I., Satoh, T., Mori, K., Hirano, S., Ikeda, M., Kurosaka, S., Ishii, J., Ishii, D., & Matsumoto, K. (2026). Defining Favorable Prognosis in Bone Metastatic Hormone‐Sensitive Prostate Cancer Treated With Androgen Receptor Signaling Inhibitors. The Prostate. https://doi.org/10.1002/pros.70152

Vancouver

Koguchi D, Tsumura H, Tabata KI, Satoh T, Mori K, Hirano S, et al. Defining Favorable Prognosis in Bone Metastatic Hormone‐Sensitive Prostate Cancer Treated With Androgen Receptor Signaling Inhibitors. The Prostate. 2026. doi:10.1002/pros.70152

BibTeX
@article{Koguchi2026,
  author = {Koguchi, Dai and Tsumura, Hideyasu and Tabata, Ken-Ichi and Satoh, Takefumi and Mori, Kohei and Hirano, Shuhei and Ikeda, Masaomi and Kurosaka, Shinji and Ishii, Junichiro and Ishii, Daisuke and Matsumoto, Kazumasa},
  title = {Defining Favorable Prognosis in Bone Metastatic Hormone‐Sensitive Prostate Cancer Treated With Androgen Receptor Signaling Inhibitors},
  journal = {The Prostate},
  year = {2026},
  doi = {10.1002/pros.70152}
}
Kostenlos starten →